Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

For patients with VEXAS syndrome and good response to azacitidine, what duration of therapy do you consider?

4
1 Answers

Mednet Member
Mednet Member
Hematology · Dalhousie University, Canada

The short answer: as long as azacitidine is controlling inflammation, reducing/eliminating steroid dependence, and/or improving cytopenias, keep using it. Don't stop (or if the patient is being bridged to alloSCT, continue until BMT).The long answer:VEXAS is an autoinflammatory disease wherein patie...

What is your approach to curative-intent therapy for a young, fit patient with newly-diagnosed monomorphic epitheliotropic intestinal T cell lymphoma (MEITL)?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Maryland Cancer Center

If >= 10% of the cells express CD30 by IHC, I would treat with BV+CHP x 6 cycles rather than CHOP according to the ECHELON-2 trial (although this trial included only 3 patients with EATL). Historically, the 5-year OS rate with anthracycline-based chemotherapy alone is approximately 10 to 20%, so for...

Would you offer definitive radiotherapy for prostate cancer (or another solid organ malignancy) to a patient on maintenance Rituximab for lymphoma?

3
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan Kettering Cancer Center

Good question and a somewhat increasingly common issue in the general sense of patients with overlapping hematologic and prostate malignancies. For starters, I would think hard about the risk group of this patient and competing risks. If this patient has an aggressive or relapsed lymphoma with favor...

What adverse events would make you switch off nivo + AVD therapy and to what second line therapy in patients with Hodgkin Lymphoma?

1
3 Answers

Mednet Member
Mednet Member
Medical Oncology · Rutgers Cancer Institute of New Jersey

The question of how to handle severe IRAEs when using the N+AVD regimen is an important one. First, of course, is to hold CPI therapy, empirically treat as indicated to avoid ongoing or worsening organ injury, and concurrently ensure that there is no other cause for the observed event(s). But if you...

What radiation dose would you use to treat a symptomatic osseous lesion secondary to AL-amyloidosis?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Boston Medical Center, Boston University School of Medicine

Extrapolating from our tracheobronchial experience, we’ve used 20 Gy in 10 fractions to target the underlying plasma cells that produce amyloid production. We’ve also used this regimen for ocular and GU (ureteric and bladder) amyloidosis. If there are obstructive or symptomatic lesions, then surgica...

What is the role of anticoagulation in patients with septic thrombophlebitis?

1
1 Answers

Mednet Member
Mednet Member
Hematology · Mayo Clinic

The role of heparin anticoagulation in septic thrombophlebitis is controversial. There are limited to no randomized trials to document outcomes. A systematic review (Falagas et al., PMID 17222406) supported this practice, and the Infectious Disease Society also supports this practice. The role of or...

How do you interpret elevations in ESR and CRP in the setting of increased BMI?

2
4 Answers

Mednet Member
Mednet Member
Rheumatology · University of Colorado School of Medicine

Increases in BMI (overweight and obesity range) have been shown to be associated with elevated CRP and ESR, with stronger associations shown with CRP specifically. Interestingly, the association between elevated CRP and obesity seems to be stronger in female populations than in male patients.In the ...

How should one monitor for and manage CMV reactivation in patients receiving alemtuzumab?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Maryland Cancer Center

Here's how I approach it: Baseline Testing: Perform CMV serology (IgG/IgM) and quantitative CMV DNA PCR before initiating alemtuzumab to establish baseline status. Frequency: Weekly PCR testing for 8–12 weeks post-infusion, focusing on the high-risk window (weeks 3–6). Extend monitoring ...

Are there specific findings that would make you suspicious of IgD or IgE monoclonal gammopathies?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Hosp of the Univ of Pennsylvania

I mostly consider an IgD or IgE monoclonal gammopathy in a patient who has a measurable serum M-spike on serum protein electrophoresis but a serum immunofixation that only shows a light chain band (either kappa or lambda). Since patients with light chain-only myeloma usually have at most a tiny mono...

How long would you anticoagulate for PE developed after air travel in a woman on an estrogen-containing vaginal ring for contraception?

1 Answers

Mednet Member
Mednet Member
Hematology · Medical University of South Carolina

This patient has two transient (“provoking”) factors that may have contributed to her pulmonary embolism (PE): the use of estrogen-containing contraception and, presumably, a recent long-haul air travel. Traditionally, it has been assumed that, after three months of treatment for the initial venous ...